Morgan Stanley Maintains Buy on BioMarin Pharmaceutical (BMRN)

​BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the Best Beaten Down Growth Stocks to Buy According to Analysts. On October 19, Sean Laaman from Morgan Stanley maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) with a price target of $104.

​The analyst likes the company’s market position and growth potential. He noted that the company’s international expansion of Voxzogo has shown revenue growth. He expects the management to continue expanding Voxzogo in other countries and noted it to be one of the key drivers for the company.

​Laaman also noted the promising pipeline of the company. He highlighted BMN 351 and BMN 333 as potential catalysts for future growth. He noted that a strong pipeline topped by BioMarin Pharmaceutical Inc. ‘s (NASDAQ:BMRN) ability to maintain its leadership in skeletal dysplasias despite the challenges further strengthens its position in the market.

​BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is an international biopharmaceutical company that develops and commercializes targeted therapies addressing the root causes of rare genetic conditions.

While we acknowledge the potential of BMRN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BMRN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.